The Comparison of Anthracyclinebased and Non-Anthracycline-Based Regimens in Adjuvant Chemotherapy of Her2-Positive Non-Metastatic Breast Cancers

The Comparison of Anthracyclinebased and Non-Anthracycline-Based Regimens in Adjuvant Chemotherapy of Her2-Positive Non-Metastatic Breast Cancers Publisher

Najafi S¹ ; Sadeghi M² ; Shajari MR¹ ; Abasvandi F¹ ; Mohebi K¹

Show Affiliations

1. Breast Diseases Department, Breast Cancer Research Centre, Motamed Cancer Institute, ACECR, Tehran, Iran
2. Medical Biology Research Centre, Kermanshah University of Medical Sciences, P.O. Box 67155-1616, Kermanshah, Iran

Source: Wspolczesna Onkologia Published:2018

Abstract

Aim of the study: This study aimed to assess the efficacy of anthracycline- based (AB) and non-anthracycline- based (nAB) adjuvant therapies in the human epidermal growth factor receptor 2 (HER2)-positive non-metastatic BC (nMBC) patients. Material and methods: This retrospective study included women with HER2-positive BCs (stage I-III) treated with trastuzumab from 2008 to 2017. The patients were divided into two groups, including 196 patients in group AB and 67 in group nAB. Results: Cox's proportional hazard regression analysis showed no unfavourable predictors for five-year overall survival (OS) and disease-free survival (DFS) except for stage and hormone therapy. The OS rate was 67.9% in group AB and 80.6% in group nAB (p = 0.630). The DFS rate was 61.6% in group AB compared with 67.1% in group nAB (p = 0.447). Conclusions: The results showed no difference between the efficacies of AB and nAB regimens in HER2-positive nMBCs in adjuvant setting. Therefore, selecting the nAB regimen can reduce the serious damage caused by the AB regimen. © 2018 Termedia Publishing House Ltd.. All rights reserved.

Style	Citing Format
MLA	Najafi S, et al.. "The Comparison of Anthracyclinebased and Non-Anthracycline-Based Regimens in Adjuvant Chemotherapy of Her2-Positive Non-Metastatic Breast Cancers." Wspolczesna Onkologia, vol. 22, no. 2, 2018, pp. 108-112.
APA	Najafi S, Sadeghi M, Shajari MR, Abasvandi F, Mohebi K (2018). The Comparison of Anthracyclinebased and Non-Anthracycline-Based Regimens in Adjuvant Chemotherapy of Her2-Positive Non-Metastatic Breast Cancers. Wspolczesna Onkologia, 22(2), 108-112.
Chicago	Najafi S, Sadeghi M, Shajari MR, Abasvandi F, Mohebi K. "The Comparison of Anthracyclinebased and Non-Anthracycline-Based Regimens in Adjuvant Chemotherapy of Her2-Positive Non-Metastatic Breast Cancers." Wspolczesna Onkologia 22, no. 2 (2018): 108-112.
Harvard	Najafi S et al. (2018) 'The Comparison of Anthracyclinebased and Non-Anthracycline-Based Regimens in Adjuvant Chemotherapy of Her2-Positive Non-Metastatic Breast Cancers', Wspolczesna Onkologia, 22(2), pp. 108-112.
Vancouver	Najafi S, Sadeghi M, Shajari MR, Abasvandi F, Mohebi K. The Comparison of Anthracyclinebased and Non-Anthracycline-Based Regimens in Adjuvant Chemotherapy of Her2-Positive Non-Metastatic Breast Cancers. Wspolczesna Onkologia. 2018;22(2):108-112.
BibTex	@article{ author = {Najafi S and Sadeghi M and Shajari MR and Abasvandi F and Mohebi K}, title = {The Comparison of Anthracyclinebased and Non-Anthracycline-Based Regimens in Adjuvant Chemotherapy of Her2-Positive Non-Metastatic Breast Cancers}, journal = {Wspolczesna Onkologia}, volume = {22}, number = {2}, pages = {108-112}, year = {2018} }
RIS	TY - JOUR AU - Najafi S AU - Sadeghi M AU - Shajari MR AU - Abasvandi F AU - Mohebi K TI - The Comparison of Anthracyclinebased and Non-Anthracycline-Based Regimens in Adjuvant Chemotherapy of Her2-Positive Non-Metastatic Breast Cancers JO - Wspolczesna Onkologia VL - 22 IS - 2 SP - 108 EP - 112 PY - 2018 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract